Sofosbuvir Archives

5 April 2017

The HepC Pill Bill

Advocacy, ARV, Guidelines, HCV, Hepatitis, Sofosbuvir 86 Views

Source : hepCoalition The HepC Pill Bill-An insight into the availability, pricing and accessibility of HCV treatment Introduction to Direct Acting Antivirals Hepatitis C treatment has remarkably evolved over the years. The previously known

23 January 2017

Amendment of the TRIPS Agreement

Advocacy, ARV, Daclatasvir, Dolutegravir, HCV, Health Financing, Hepatitis, HIV, Intellectual Proprety, Pathology, Sofosbuvir, TB 73 Views

WTO members on 6 December 2005 approved changes to the WTO’s intellectual property (TRIPS) agreement in order to make permanent a decision on patents and public health originally adopted in 2003. This was formally

26 June 2015

Launch of Moroccan Generic Sofosbuvir: A Victory for the Wide-spread Use HCV Treatmen…

ARV, Daclatasvir, HCV, Hepatitis, Intellectual Proprety, Morocco, North Africa, Sofosbuvir 104 Views

According to the Ministry of Health, 625,000 people are infected by HCV, 1.6% of the general population of Morocco. Of those infected, 267,000 people have active chronic infection requiring treatment. Until recently, the management

20 May 2015

Treatment Advocates Denounce Gilead’s Embargo against Thousands of Tunisians Sufferin…

Advocacy, ARV, Daclatasvir, HCV, Health Financing, Hepatitis, Intellectual Proprety, News, North Africa, Sofosbuvir 72 Views

The Tunisian Association of Fight against STDs and AIDS (ATL Tunis) and the International Treatment Preparedness Coalition in MENA Region (ITPC-MENA) denounce the refusal of Gilead Sciences to make their drug against the Hepatitis